...
首页> 外文期刊>Immunology: An Official Journal of the British Society for Immunology >Treg programming and therapeutic reprogramming in cancer
【24h】

Treg programming and therapeutic reprogramming in cancer

机译:Treg编程和治疗癌症重新编程

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Overcoming the immunosuppressive tumour microenvironment is the major challenge impeding cancer immunotherapy today. Regulatory T‐cells (Tregs) are prevalent in nearly all cancers and, as immunosuppressive regulators of immune responses, they are the principal opponents of cancer immunotherapy. However, disabling Tregs systemically causes severe autoimmune toxicity, hastening the need for more selective methods to target intratumoural Tregs. In this review, we discuss a burgeoning new modality to specifically target tumour‐infiltrating Tregs ( TI ‐Tregs) by reprogramming their functionality from immunosuppressive to immune stimulatory within tumours. As the basis for therapeutic selectivity of TI ‐Tregs, we will focus on the defining features of Tregs within cancer: their highly activated state controlled by the engagement of key surface receptors, their distinct metabolic programme, and their unique transcriptional programme. By identifying proteins and pathways that distinguish TI ‐Tregs from other Tregs in the body, as well as from the beneficial antitumour effector T‐cells within tumours, we highlight mechanisms to selectively reprogramme TI ‐Tregs for the treatment of cancer.
机译:发明内容克服免疫抑制肿瘤微环境是目前患有癌症免疫疗法的主要挑战。调节性T细胞(Tregs)在几乎所有癌症中普遍存在,作为免疫反应的免疫抑制因素,它们是癌症免疫疗法的主要对手。然而,禁用Tregs系统性地引起严重的自身免疫毒性,加速需要更多选择性方法来靶向肿瘤瘤。在本文中,我们讨论了一种新的态度,以通过将其在免疫抑制作用中的免疫刺激进行重新编程以在肿瘤中进行重编程来特异性地靶向肿瘤渗透的Tregs(Ti -tregs)。作为Ti -Tregs治疗选择性的基础,我们将专注于癌症内Tregs的定义特征:通过关键表面受体的接合,它们不同的代谢程序和其独特的转录程序来控制的高度激活状态。通过鉴定蛋白质和途径,即将Ti -Tregs与身体中的其他Tregs区分开,以及从肿瘤内的有益抗肿瘤效应T细胞中,我们突出了选择性地编程为癌症治疗方法的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号